Greenfire Resources Ltd. Common Shares GFR 深 沪
等待开盘 07-23 09:30:00 美东时间
4.41
+0.050
+1.15%
华盛通- 最 高4.43
- 今 开4.37
- 成交量 2.23万股
- 最 低 4.26
- 昨 收 4.36
- 总市值 3.10亿
- 52周最高 8.1599
- 市盈率 静 3.56
- 换手率 0.03%
- 52周最低 3.81
- 委 比 0.00%
- 总股本 7023.00万
- 历史最高 9.8991
- 量 比 0.44
- 振 幅 3.90%
- 历史最低 3.81
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报季“开门红”提振信心 美股三大期指小幅上涨 | 今夜看点
①台积电日本熊本第二工厂将在今年稍晚动工； ②Waymo在美国得州奥斯汀扩大无人驾驶服务范围； ③必和必拓年度铁矿石和铜产量均创历史新高。
07-18 20:48
ProKidney Confirms Alignment With FDA On Accelerated Approval Pathway For Rilparencel
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for
07-15 19:31
ProKidney (PROK) Shares Skyrocket On Promising Kidney Disease Drug Trial Results
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday driven by positive clinical trial data for its CKD treatment.
07-09 23:41
Galliford Try Expects 2025 Performance to Surpass Expectations
Galliford Try ( ($GB:GFRD) ) just unveiled an announcement. Galliford Try Holdi...
07-09 14:22
Why Is Penny Stock ProKidney Stock Trading Higher On Tuesday?
ProKidney stock jumps after Phase 2 trial shows rilparencel significantly slowed kidney function decline in patients with chronic kidney disease and diabetes.
07-08 21:05
ProKidney spikes after mid-stage trial data for lead asset
Shares of ProKidney (NASDAQ:PROK) climbed ~56% in the premarket on Tuesday after the cell therapy developer announced positive topline results from a mid-stage trial for its lead candidate, rilparence...
07-08 20:04
资金即将见底，Sangamo努力自救
在新型基因编辑技术不断涌现的发展浪潮中，坚守锌指核酸酶（ZFN）技术的基因编辑先驱者Sangamo，连续地被合作伙伴放弃（包括赛诺菲、诺华、渤健和辉瑞），股价也...
06-25 13:00
